BACE1 and early-onset autosomal dominant Alzheimer disease: Since the identification of β-secretase (memapsin 2, BACE1) more than a decade ago, significant research effort from many laboratories around the world has been directed towards the development of inhibitor drugs against this β-secretase as a potential treatment of Alzheimer's disease (AD) [1].